Background: Previous clinical trial has demonstrated that rivaroxaban is non-inferior to
warfarin for preventing stroke and systemic embolism in patients with nonvalvular atrial …

Background: Rivaroxaban was shown to be effective in reducing the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (AF) in a randomized …

Background: Rivaroxaban is a novel oral anticoagulant approved in the US in 2011 for
prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation …

Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …

Background: Although randomized trials demonstrate the noninferiority of rivaroxaban
compared with warfarin in the context of nonvalvular atrial fibrillation (AF), little is known …

The objective of this study is to evaluate the effectiveness of different rivaroxaban dosage
regimens in preventing ischemic stroke and systemic thromboembolism among Asians. A …

Introduction: Rivaroxaban emerged as potential alternatives to warfarin for the prevention of
thromboembolisim in patients with atrial fibrillation (AF). Because of the concern for the risk …

Background Effectiveness of rivaroxaban vs warfarin in patients with non-valvular atrial
fibrillation (NVAF) is not well-understood over long follow up time in real-world settings. This …

Background: Little data exists regarding the effectiveness and safety of rivaroxaban or
apixaban versus warfarin in nonvalvular atrial fibrillation (NVAF) patients treated outside of …

Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …